Roger Emert, MD
Allergy & Immunology · New York, NYNPI 1184623134
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Gilead accounts for 72.4% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $381 and has fallen 90.8% since, to $35 in 2024. That places this record below the midpoint for allergy & immunology clinicians in NY, where the typical reported total is $2,174.
Across 34 payments — averaging $21.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$531
- Novo Nordisk$142
- Antares Pharma, Inc.$21
- Alkermes, Inc.$20
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$20
What the payments were for
- Food & beverage$733100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 23 | $531 |
| Novo Nordisk | 8 | $142 |
| Antares Pharma, Inc. | 1 | $21 |
| Alkermes, Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
How this compares
$733 in reported general payments places this provider in the 30th percentile of 320 allergy & immunology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 306 | $1,286,498 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 23 | $86,533 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 23 | $82,847 |
| DescovyEmtricitabine/Tenofov Alafenam | 30 | $71,083 |
| OzempicSemaglutide | 31 | $40,195 |
| EliquisApixaban | 25 | $33,286 |
| XolairOmalizumab | 12 | $31,075 |
| Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf) | 21 | $20,109 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $13,160 |
| MounjaroTirzepatide | 11 | $11,070 |
| Testosterone | 53 | $6,494 |
| Atorvastatin Calcium | 324 | $2,941 |
| ValacyclovirValacyclovir Hcl | 81 | $2,900 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 19 | $2,087 |
| Diclofenac Sodium | 22 | $1,621 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $531 | $1,444,115359 claims |
| Novo NordiskOzempic | $142 | $40,19531 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 320 allergy & immunology providers in New York.
Other allergy & immunology in New York
- Ujwala KazaNew York$1.1M
- Robert SporterNew York$946K
- Richard InselNew York$269K
- Purvi ParikhNew York$183K
- Arthur LubitzNew York$165K
- Ama AlexisNew York$120K
- Boyan HadjievNew York$97K
- Charlotte Cunningham-RundlesNew York$95K
- Paula BusseNew York$95K
- Hale YarmohammadiNew York$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.